

CLAIMS

1. A pharmaceutical composition for use in treating fibrosis, the composition comprising a therapeutically effective amount of the compound having the structure:




wherein R_1 is a direct bond; or C1-C12 straight alkyl or branched alkyl, optionally substituted with at least one halogen atom selected from fluorine, chlorine and bromine, a hydroxy group, a carboxyl group, an amine group or a benzyl group, ; R_2 is hydrogen or fluorine; R_3 is a hydrogen or methyl group, and R_4 is a hydroxyl group or a ketone group; and wherein the dotted line represents a single or double bond, and at least one pharmaceutically acceptable carrier.

2. The composition according to claim 1 wherein R_1 is a non-substituted C1-C10 alkyl group.
3. The composition according to claim 2 wherein R_1 is a non-substituted $(CH_2)_3$ group.
4. The composition according to claim 1, 2, or 3 wherein R_2 and R_3 are H and R_4 is a ketone group, and the dotted line is a double bond.
5. The composition according to claim 1, 2, or 3 wherein R_2 is fluorine, R_3 is methyl and R_4 is a hydroxyl group, and the dotted line is a double bond.
6. The composition according to claim 1, 2, or 3 wherein R_2 is H, R_3 is H and R_4 is a hydroxyl group, and the dotted line is a single bond.
7. The composition according to claim 1, 2, or 3 wherein R_2 is H, R_3 is H and R_4 is a ketone group, and the dotted line is a single bond.
8. The composition according to claim 1, wherein the compound has the structure:



.

9. The composition according to any one of the previous claims, wherein fibrosis is fibrosis of the lung, liver, kidney, heart, muscle, skin, ovaries, or testes.
10. The composition according to claim 9 wherein fibrosis is fibrosis of the lung.
11. The composition according to any one of the previous claims for treatment of pulmonary fibrosis associated with COVID-19.
12. The composition according to any one of the previous claims, wherein the compound is administered in an amount of between 10 mg/day and 30 mg/day.
13. A composition for use in treatment of COVID-19 comprising administering to a patient in need thereof between 10 mg/day and 30 mg/day of a compound 1 having the structure:



.

14. The composition according to claim 13 wherein the patient is administered 20 mg/day of compound 1.
15. The composition according to claim 13 or 14 wherein the patient is suffering from moderate COVID-19.

16. The composition according to any one of claims 13-15 wherein compound 1 is administered for at least three consecutive days.
17. The composition according to any one of claims 13-16 wherein the patient's recovery improves relative to treatment with dexamethasone.
18. The composition according to any one of claims 13-17 wherein the patient is also receiving a treatment of at least one of: oxygen enrichment, hydration, anti-pyretics, antitussive, multivitamins. antimicrobial agents for co-infections, ivermectin, remdesivir, baricitinib, tofacitinib, tocilizumab, sarilumab.
19. The composition according to any one of claims 13-18 wherein the compound 1 is administered intravenously.
20. The composition according to any one of claims 13-19 wherein the patient does not experience hyperglycemia after administration.
21. The composition according to any one of claims 13 to 20 wherein the patient is suffering from the effects of long COVID-19.
22. The composition according to any one of claims 13 to 21 wherein the patient is further administered standard of care.
23. The composition according to any one of claims 13 to 22 wherein compound 1 is administered for only 3 days.
24. The compositions according to any one of claims 13 to 23 wherein the administration of compound 1 continues at a constant rate, without tapering.